GAD-Alum

DRUG4 trials

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Oslo University Hospital, Johnny Ludvigsson

Conditions

AutoimmunityDiabetes Mellitus, Type 1Diabetes, Type IEnterovirus InfectionsType 1 Diabetes Mellitus

Phase 1

GAD-Alum (Diamyd) Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes (DIAGNODE-1)

CompletedNCT02352974

Johnny LudvigssonDiabetes Mellitus, Type 1

Start: 2015-01-31End: 2019-10-31Updated: 2020-04-27

Phase 2

Effects of Recombinant Human Glutamic Acid Decarboxylase on the Progression of Type 1 Diabetes in New Onset Subjects

CompletedNCT00529399

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Type 1 Diabetes Mellitus

Start: 2009-02-28End: 2012-05-31Updated: 2020-05-07

Diabetes Virus Detection Project, Intervention With GAD-alum

TerminatedNCT01129232

Oslo University HospitalAutoimmunity, Diabetes, Type I, Enterovirus Infections

Start: 2011-01-31End: 2013-01-31Updated: 2018-05-17

EDCR Study - Etanercept Diamyd Combination Regimen -Open Trial to Evaluate Safety in Children With Type 1 Diabetes

CompletedNCT02464033

Johnny LudvigssonDiabetes Mellitus, Type 1

Start: 2015-05-31End: 2019-02-25Updated: 2021-03-29

Related Papers

Intralymphatic GAD-Alum (Diamyd®) Improves Glycemic Control in Type 1 Diabetes With HLA DR3-DQ2

The Journal of Clinical Endocrinology & Metabolism2022-06-0629 citations

Glutamic Acid Decarboxylase Injection Into Lymph Nodes: Beta Cell Function and Immune Responses in Recent Onset Type 1 Diabetes Patients

Frontiers in Immunology2020-10-0932 citations

Intralymphatic Glutamic Acid Decarboxylase-Alum Administration Induced Th2-Like-Specific Immunomodulation in Responder Patients: A Pilot Clinical Trial in Type 1 Diabetes

Journal of Diabetes Research2018-01-0126 citations

Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.

2011-06-27276 citations